Camrelizumab

Generic Name: Camrelizumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1798286-48-2

Unique Ingredient Identifier: 73096E137E

Background: Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Indication: ⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。

⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。

⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。

⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Feasibility and safety of PD-1 blockades among elderly patients with p

Study evaluates PD-1 blockade efficacy and tolerability in elderly patients with metastatic esophageal squamous cell carcinoma (ESCC), finding ORR of 23.1% and median OS of 10.9 months, suggesting PD-1 blockades as a viable option for this population.

clinicaltrialsarena.com

3 months ago

Anlotinib and penpulimab gather attention in HCC with APOLLO results

The APOLLO trial at ESMO 2024 showed Chia Tai Tianqing's Focus V and Akeso's penpulimab significantly improved PFS and OS in advanced hepatocellular carcinoma (aHCC) compared to sorafenib, with a manageable safety profile. This contrasts with the failure of Merck & Co's Keytruda in the LEAP-002 trial. Competitive IO-TKIs like Elevar Therapeutics' camrelizumab and rivoceranib also showed benefits but with more TRAEs. Roche's Tecentriq with bevacizumab remains the first-line standard-of-care in aHCC, posing a challenge to new IO-TKI combinations.

Camrelizumab

Feasibility and safety of PD-1 blockades among elderly patients with p

Anlotinib and penpulimab gather attention in HCC with APOLLO results

Drug Development Updates